Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

54.08 -1.00 (-1.82%)

Streaming Delayed Price Updated: 12:47 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

34 35 Next >

7 Biotech Stocks to Get In Now Before Investors Catch On ↗

October 23, 2023

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

Via InvestorPlace

CRISPR Therapeutics Stock: Bull vs. Bear ↗

October 21, 2023

Here's the scoop on one of the most widely followed gene-editing stocks on the market.

Via The Motley Fool

Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time ↗

October 21, 2023

Wood is going all in on gene editing.

Via The Motley Fool

3 Gene Editing Stocks to Generate Super-Charged Gains ↗

October 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

Via InvestorPlace

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗

October 18, 2023

The company can begin a pivotal study of its treatment for cardiomyopathy.

Via Investor's Business Daily

Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On? ↗

October 17, 2023

Via Benzinga

Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges ↗

October 17, 2023

Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches...

Via Benzinga

Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst ↗

October 17, 2023

Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw

Via Benzinga

Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy ↗

October 17, 2023

Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Ov

Via Benzinga

This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street ↗

October 16, 2023

This Wood favorite is heading for a big moment.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

2 Growth Stocks That Could Double Your Money, According to Wall Street ↗

October 15, 2023

Find out why investment bank analysts are pounding the table on these stocks.

Via The Motley Fool

2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years ↗

October 14, 2023

These two gene-editing stocks could be diamonds in the rough.

Via The Motley Fool

Cathie Wood's Ark Invest Sells $9.8M Worth Of Tesla Shares — Second Day Of Selling EV Giant In A Row ↗

October 11, 2023

Via Benzinga

Cathie Wood's Ark Invest Keeps On Cutting Tesla Holdings, Sells More Than $8M Worth Of EV Maker's Shares ↗

October 10, 2023

Via Benzinga

Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You? ↗

October 10, 2023

Wood has outperformed the market so far this year.

Via The Motley Fool

Cathie Wood Goes Shopping For Stock of Jack Dorsey's Block — Ark Invest Bolsters Portfolio With Archer Aviation, CRISPR Shares ↗

October 09, 2023

Via Benzinga

3 No-Brainer Growth Stocks to Buy in October ↗

October 07, 2023

The time is right to invest in these great stocks.

Via The Motley Fool

2 Growth Stocks That Can Rocket 98% to 108% Higher, According to Wall Street ↗

October 05, 2023

The analysts who follow these stocks have some big expectations for the year ahead.

Via The Motley Fool

Cathie Wood's Ark Invest Sells Over $25M Worth Of Tesla Shares Amid Boost In Price ↗

October 04, 2023

Via Benzinga

Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich ↗

October 03, 2023

Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich.

Via InvestorPlace

Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead? ↗

October 03, 2023

The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome.

Via The Motley Fool

2 Top Biotech Stocks to Buy in October ↗

October 03, 2023

Growth catalysts lie ahead for both of these players.

Via The Motley Fool

Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics ↗

October 02, 2023

The better of the pair should be able to beat Bluebird Bio.

Via The Motley Fool

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

October 01, 2023

These companies are helping change medicine; they could make boatloads of money along the way.

Via The Motley Fool

3 Cathie Wood Stocks Set to Explode Higher ↗

October 01, 2023

Delve into the exciting world of Cathie Wood Stocks where potential meets performance, offering investors hefty long-term upside.

Via InvestorPlace

Futurescape: Betting Big on These 3 Next-Gen Tech Stocks ↗

October 01, 2023

These next-gen tech stocks that emphasize forward-thinking innovation are perfect for investors who seek big bets or massive gains.

Via InvestorPlace

3 No-Brainer Growth Stocks to Buy in October ↗

October 01, 2023

These three top mid-cap stocks could be poised for a long-tailed growth spurt.

Via The Motley Fool

Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock ↗

September 29, 2023

Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.

Via Benzinga

Why Editas Medicine Stock Is Soaring Today ↗

September 29, 2023

Investors are cheering a big analyst upgrade for the gene-editing stock.

Via The Motley Fool

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.